These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 12434602)

  • 1. [Malignant lymphomas].
    Fermé C
    Rev Prat; 2002 Oct; 52(15):1711-8. PubMed ID: 12434602
    [No Abstract]   [Full Text] [Related]  

  • 2. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience.
    Escalón MP; Liu NS; Yang Y; Hess M; Walker PL; Smith TL; Dang NH
    Cancer; 2005 May; 103(10):2091-8. PubMed ID: 15816054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The determination of the beta 2-microglobulin level in malignant lymphomas].
    Balashov AT; Dukal'tetenko EV; Polezhaev IuN
    Ter Arkh; 1992; 64(7):52-3. PubMed ID: 1440369
    [No Abstract]   [Full Text] [Related]  

  • 4. Serum soluble interleukin-2 receptor, beta2-microglobulin, lactate dehydrogenase and erythrocyte sedimentation rate in children with Hodgkin's lymphoma.
    Bien E; Balcerska A
    Scand J Immunol; 2009 Nov; 70(5):490-500. PubMed ID: 19874554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Malignant lymphoma--there are still many open questions].
    Buske C; Hiddemann W
    Internist (Berl); 2007 Apr; 48(4):349-50. PubMed ID: 17361404
    [No Abstract]   [Full Text] [Related]  

  • 6. [Gastrointestinal lymphoma].
    Fischbach W; Daum S
    Dtsch Med Wochenschr; 2003 Sep; 128(37):1899-901. PubMed ID: 12970824
    [No Abstract]   [Full Text] [Related]  

  • 7. [BCG vaccination in the treatment of malignant non-Hodgkin lymphomas].
    Gociu M; Ciocoiu A; Moţoiu I; Drăghici D; Dumitrescu A; Costescu M; Berceanu S
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1984; 36(1):25-8. PubMed ID: 6145202
    [No Abstract]   [Full Text] [Related]  

  • 8. [Treatment for NK-cell lymphoma].
    Yamaguchi M
    Rinsho Ketsueki; 2004 Mar; 45(3):209-17. PubMed ID: 15103934
    [No Abstract]   [Full Text] [Related]  

  • 9. Presence of a high-grade component in gastric mucosa-associated lymphoid tissue (MALT) lymphoma is not associated with an adverse prognosis.
    Ang MK; Hee SW; Quek R; Yap SP; Loong S; Tan L; Tao M; Lim ST
    Ann Hematol; 2009 May; 88(5):417-24. PubMed ID: 18777110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Central nervous system dissemination in immunocompetent patients with aggressive lymphomas: incidence, risk factors and therapeutic options.
    Ferreri AJ; Assanelli A; Crocchiolo R; Ciceri F
    Hematol Oncol; 2009 Jun; 27(2):61-70. PubMed ID: 19247977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravascular lymphoma masquerading as Vogt-Koyanagi-Harada syndrome.
    Pahk PJ; Todd DJ; Blaha GR; Soukiasian SH; Landmann DS; Craven DE; Tronic BS; Zabar Y; Marx JL
    Ocul Immunol Inflamm; 2008; 16(3):123-6. PubMed ID: 18569804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [WHO-classification of malignant lymphomas].
    Rüdiger T; Müller-Hermelink HK
    Radiologe; 2002 Dec; 42(12):936-42. PubMed ID: 12486547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncologic outcomes of primary lymphoma of bone in adults.
    Lewis VO; Primus G; Anastasi J; Doherty D; Montag AG; Peabody TD; Simon MA
    Clin Orthop Relat Res; 2003 Oct; (415):90-7. PubMed ID: 14612634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Malignant lymphoma--recent progress in diagnosis and treatment. 3. Progress in therapeutic results. (3). Present status and problems of treatment of malignant lymphoma in Japan].
    Sakano T
    Nihon Naika Gakkai Zasshi; 1983 Oct; 72(10):1336-41. PubMed ID: 6676405
    [No Abstract]   [Full Text] [Related]  

  • 15. Could beta-2-microglobulin be a useful diagnostic tool in malignant lymphoma and other haematological malignancy?
    Krc I; Fischerová E
    Acta Univ Palacki Olomuc Fac Med; 1985; 108():231-8. PubMed ID: 3161281
    [No Abstract]   [Full Text] [Related]  

  • 16. [Prognostic factors and predictive model of malignant lymphoma].
    Shimoyama M
    Nihon Naika Gakkai Zasshi; 1994 Jun; 83(6):933-9. PubMed ID: 7964044
    [No Abstract]   [Full Text] [Related]  

  • 17. Prognostic significance of morphological subtypes in canine malignant lymphomas during chemotherapy.
    Ponce F; Magnol JP; Ledieu D; Marchal T; Turinelli V; Chalvet-Monfray K; Fournel-Fleury C
    Vet J; 2004 Mar; 167(2):158-66. PubMed ID: 14975390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Central nervous system-directed preventative therapy in adults with lymphoma.
    McMillan A
    Br J Haematol; 2005 Oct; 131(1):13-21. PubMed ID: 16173958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Exploration of prognostic factors in extranodal nasal-type NK/T cell lymphoma].
    Han DM; Chen XQ; Bai QX
    Zhonghua Zhong Liu Za Zhi; 2006 Feb; 28(2):137. PubMed ID: 16750021
    [No Abstract]   [Full Text] [Related]  

  • 20. Diagnostic factors in intermediate and high-grade lymphomas: pathologic, immunologic, and clinical.
    Bunn PA
    J Clin Oncol; 1988 Jul; 6(7):1073-5. PubMed ID: 2899139
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.